» Articles » PMID: 2456581

Differential Loss of Striatal Projection Neurons in Huntington Disease

Overview
Specialty Science
Date 1988 Aug 1
PMID 2456581
Citations 348
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington disease (HD) is characterized by the loss of striatal projection neurons, which constitute the vast majority of striatal neurons. To determine whether there is differential loss among different populations of striatal projection neurons, the integrity of the axon terminal plexuses arising from the different populations of substance P-containing and enkephalin-containing striatal projection neurons was studied in striatal target areas by immunohistochemistry. Analysis of 17 HD specimens indicated that in early and middle stages of HD, enkephalin-containing neurons projecting to the external segment of the globus pallidus were much more affected than substance P-containing neurons projecting to the internal pallidal segment. Furthermore, substance P-containing neurons projecting to the substantia nigra pars reticulata were more affected than those projecting to the substantia nigra pars compacta. At the most advanced stages of the disease, projections to all striatal target areas were depleted, with the exception of some apparent sparing of the striatal projection to the substantia nigra pars compacta. These findings may explain some of the clinical manifestations and pharmacology of HD. They also may aid in identifying the neural defect underlying HD and provide additional data with which to evaluate current models of HD pathogenesis.

Citing Articles

The striatal compartments, striosome and matrix, are embedded in largely distinct resting state functional networks.

Sadiq A, Funk A, Waugh J bioRxiv. 2025; .

PMID: 39763746 PMC: 11702670. DOI: 10.1101/2024.12.13.628392.


Break-up and recovery of harmony between direct and indirect pathways in the basal ganglia: Huntington's disease and treatment.

Kim S, Lim W Cogn Neurodyn. 2024; 18(5):2909-2924.

PMID: 39555304 PMC: 11564723. DOI: 10.1007/s11571-024-10125-w.


Restoring Compromised Cl in D2 Neurons of a Huntington's Disease Mouse Model Rescues Motor Disability.

Serranilla M, Pressey J, Woodin M J Neurosci. 2024; 44(50).

PMID: 39500579 PMC: 11638812. DOI: 10.1523/JNEUROSCI.0215-24.2024.


Impaired striatal glutathione-ascorbate metabolism induces transient dopamine increase and motor dysfunction.

Malik M, Guo F, Asif-Malik A, Eftychidis V, Barkas N, Eliseeva E Nat Metab. 2024; 6(11):2100-2117.

PMID: 39468205 PMC: 11599059. DOI: 10.1038/s42255-024-01155-z.


Pathogenic Huntingtin aggregates alter actin organization and cellular stiffness resulting in stalled clathrin-mediated endocytosis.

Singh S, Rajput S, Sharma A, Kataria S, Dutta P, Ananthanarayanan V Elife. 2024; 13.

PMID: 39382268 PMC: 11643626. DOI: 10.7554/eLife.98363.


References
1.
Lange H, Thorner G, Hopf A, Schroder K . Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci. 1976; 28(4):401-25. DOI: 10.1016/0022-510x(76)90114-3. View

2.
Beckstead R, Cruz C . Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience. 1986; 19(1):147-58. DOI: 10.1016/0306-4522(86)90012-6. View

3.
Spokes E . Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain. 1980; 103(1):179-210. DOI: 10.1093/brain/103.1.179. View

4.
Emson P, Arregui A, Sandberg B, Rossor M . Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res. 1980; 199(1):147-60. DOI: 10.1016/0006-8993(80)90237-1. View

5.
Buck S, Burks T, Brown M, Yamamura H . Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease. Brain Res. 1981; 209(2):464-9. DOI: 10.1016/0006-8993(81)90171-2. View